Form 4: Sutro Biopharma Director, John Gordon Freund, Acquires 35,000 Stock Options

Director John Gordon Freund acquired 35,000 stock options in Sutro Biopharma, Inc. on June 6, 2024.

Summary

• On June 6, 2024, John Gordon Freund, a director of Sutro Biopharma, Inc., acquired 35,000 stock options.
• The options have an exercise price of $3.76.
• The options vest monthly starting July 6, 2024, at a rate of 8.33% of the total award.
• The options will be fully vested and exercisable by the earlier of the company's 2025 annual stockholders meeting or June 6, 2025, contingent upon Freund's continued service to the issuer.
• The expiration date for these options is June 6, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard transaction (stock option grant) that aligns the director's interests with the company's success. There are no explicitly negative elements.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies continued service from the director until at least June 2025.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common in the biopharmaceutical industry, where equity compensation is frequently used to incentivize executives and directors.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biopharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their compensation packages for directors and executives.
• The vesting schedule and exercise price are typical for such grants, aligning the director's interests with those of the shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates